|
| Exchange Received Time 02/03/2017 14:17:19 Exchange Disseminated Time 02/03/2017 14:17:22 Time Taken 00:00:03 | | Dear Sir / Madam, We wish to inform that the USFDA inspected our formulations manufacturing facility at Baddi from 20th February 2017 to 1st March 2017. At the end of the inspection, there were 3 observations given under form 483. All these three observations are related to Pre-Approval Inspection (PAI) for a specific product filed. This product is yet to be manufactured or marketed in the US. The company is already in the process of responding to the PAI observations. Apart from above product related observations, there are no observations related to cGMP practices. Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large. |
|
|